绥美凯的适应症

(Dolutea Paramide Tablets) is suitable for the treatment of adults and adolescents over 12 years old (with a body weight of at least 40 kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B5701 allele, he should not take products containing abacavir.

Dolutegravir is a once-daily three-in-one drug developed by ViiV Healthcare, a joint venture between GlaxoSmithKline and Pfizer. The drug is based on the treatment plan of the integrase inhibitor Tivicay (Dolutegravir) and also contains two nucleoside reverse transcriptase inhibitors, Abacavir and Lamivudine. It was approved by the FDA on August 27, 2014. On January 22, 2018, GlaxoSmithKline (GSK) announced that its single-tablet compound preparation dolutegravir (Triumeq), which is based on the new generation integrase inhibitor dolutegravir (DTG) and is used to treat HIV, was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.

At present, Suimeike (dolute abalamib tablets) has been approved in more than 100 countries, and has been recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. Dr. Wim Swyzen, MD, head of medical affairs and vice president of GSK China/Hong Kong, said, "Through effective HIV drug treatment, the lifespans of HIV patients and healthy people are getting closer and closer. Drug compliance and convenience of medication play an increasingly important role in further improving the quality of life of patients. Currently, there is no drug that can be taken once a day or one tablet at a time on the Chinese market. The approval of Suimeike (dolute abalamib tablets) fills this gap and meets the urgent need for convenient medication use by doctors and patients."

It can be seen that (Dolutea Paramid Tablets) is a new drug used to treat AIDS and brings new hope to AIDS patients. AIDS is an infectious disease that can be transmitted through sexual contact, blood, and mother-to-child transmission. Currently, there is still a lack of effective drugs to cure HIV infection worldwide. Suimeikai (Dolutea Paramid Tablets) can only reduce the viral load to the maximum and lasting extent and improve the patient's quality of life.